Endocrine therapy (ET) is the initial therapy for HR+ patients. Primary endocrine resistance (PER) is defined as a relapse while on the first 2 years of adjuvant ET, or PD within first 6 months of first-line ET for MBC; secondary endocrine resistance (SER) is defined as: relapse while on adjuvant ET but after the first 2 years, or relapse within 12 months of completing adjuvant ET, or PD > 6months after initiating ET for MBC. One of the available therapeutic strategy is FUL, which demonstrated in a recent Phase III trial, PFS was significantly longer in the FUL group than in the ANA group (16.6 vs 13.8 months). Aim of the present analysis is to describe pts’ characteristics and clinical outcome in a population of endocrine-pretreated pts who received FUL as 1st-line therapy in a real-life setting.
First-line therapy with fulvestrant (FUL) in HR+ve, HER2-ve advanced pre-treated breast cancer (ABC) patients (pts): Results from the GIM-13 AMBRA Study
Clara Natoli;
2018-01-01
Abstract
Endocrine therapy (ET) is the initial therapy for HR+ patients. Primary endocrine resistance (PER) is defined as a relapse while on the first 2 years of adjuvant ET, or PD within first 6 months of first-line ET for MBC; secondary endocrine resistance (SER) is defined as: relapse while on adjuvant ET but after the first 2 years, or relapse within 12 months of completing adjuvant ET, or PD > 6months after initiating ET for MBC. One of the available therapeutic strategy is FUL, which demonstrated in a recent Phase III trial, PFS was significantly longer in the FUL group than in the ANA group (16.6 vs 13.8 months). Aim of the present analysis is to describe pts’ characteristics and clinical outcome in a population of endocrine-pretreated pts who received FUL as 1st-line therapy in a real-life setting.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
